Concepedia

H. I. Scher

HI

Statistics

Publications

2

Citations

1.5K

H-Index

2

Active since

2011

Affiliations

Sidney Kimmel Comprehensive Cancer Center(Current)

H. I. Scher is an author at Sidney Kimmel Comprehensive Cancer Center specializing in oncology, castration-resistant prostate cancer therapy, and metastatic castration-resistant prostate cancer.

Publications per year

2011–2014

2

Publications

2

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher et al. · The Lancet Oncology · 2014 · 1.5K citations · Full text

, , +16

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.

H. I. Scher, Gerhard Fischer Wolf‐Dieter Heller, A. Molina et al. · Journal of Clinical Oncology · 2011 · 23 citations

, , +17

1–2 of 2